Scancell Holdings Plc SCLP
LSE · United Kingdom · Health Technology
GBp 9.35-0.05 (-0.53%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) told investors it has secured up to US$25 million of debt financing from funds and accounts managed by BlackRock, bolstering the funding package for the registrational Phase 3 trial of its lead melanoma treatment iSCIB1+. The company plans...
OXFORD, United Kingdom and BURLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) (“Scancell”, or the “Company”), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that, further to its announcement on 23 July 2026 regarding the planned merger with Neuphoria Therapeutics Inc. (“Neuphoria”) and financing to conduct the registrational Phase 3
A landmark trial success for Moderna and Merck's cancer vaccine has strengthened the case for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the immuno-oncology company developing a rival melanoma treatment, according to one broker covering the sector's innovative small-caps. Merck and...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.